CYP19A1 and breast cancer: In consequence, on March 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to palbociclib for the treatment of postmenopausal metastatic HR-positive BC patients in combination with an aromatase inhibitor as the initial endocrine-based therapy.